FDA Advisers Request More Data for Drug Trialed in China, Citing Lack of Diversity and Different Standards

Recently, an advisory committee of the U.S. Food and Drug Administration voted in favor of requiring additional trial data in order for a China-trialed medicine to obtain FDA approval. This decision could have major implications for future regulatory approval applications for medicines developed in China. The FDA's positions and the considerations of the committee members are summarized below.